Update on Fujii: Anesthesia journal finds overwhelming statistical evidence of data fabrication

There’s a bit more this afternoon on the story of Yoshitaka Fujii, the Japanese anesthesiologist accused of fraud and other misconduct that we reported on yesterday.

The British journal Anaesthesia, which has been looking into Fujii’s research record, has posted four articles and editorials about the case and related issues on its website. One in particular is remarkable for its conclusions. Written by a UK anesthesiologist named John Carlisle, the article claims to have analyzed 169 randomized controlled trials that Fujii conducted between 1991 and 2011.

According to the abstract (which we formatted for readability, and which should be online shortly, we’re told): Continue reading Update on Fujii: Anesthesia journal finds overwhelming statistical evidence of data fabrication

Major fraud probe of Japanese anesthesiologist Yoshitaka Fujii may challenge retraction record

We have learned that a widely published Japanese anesthesiologist is under investigation by his university over concerns that he engaged in repeated fraud for decades that has tainted roughly 180 articles—many of which may be retracted as a result.

In a related move, the journal Clinical Therapeutics is retracting papers by the researcher, Yoshitaka Fujii, most recently of Toho University, in Tokyo. Judy Pachella, managing editor of the journal, confirmed the retractions but would not state how many papers were affected. Clinical Therapeutics published 17 articles by Fujii, between 2003 and 2010.

Continue reading Major fraud probe of Japanese anesthesiologist Yoshitaka Fujii may challenge retraction record

Another withdrawal by MD Anderson’s Aggarwal, again for unclear reasons

Bharat B. Aggarwal, the MD Anderson researcher under investigation at his institution over concerns of image manipulation, has withdrawn a second paper, although you’d never know why from the statement.

The notice for the article, “Evidence for the critical roles of NF-κB p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells,” is pretty minimal: Continue reading Another withdrawal by MD Anderson’s Aggarwal, again for unclear reasons

Author who took responsibility for errors in retracted PNAS paper cites it…in error

via Wikimedia

One of the issues we’ve touched on at Retraction Watch is what happens once papers are retracted. A few studies have found that other authors continue to cite those studies anyway, without noting their withdrawal from the literature. A more recent paper found that retractions are linked to a dramatic decline in citations (see last half of post). And we’ve reported on one case in which the authors of a retracted study decided not to cite it at all when they republished their findings elsewhere.

But it seems unusual for an author to cite his or her own retracted work without noting it had been retracted. That’s what happened in a recently published PLoS ONE paper, “Loss of Secreted Frizzled-Related Protein 4 Correlates with an Aggressive Phenotype and Predicts Poor Outcome in Ovarian Cancer Patients.” The second to last paragraph of that paper ends: Continue reading Author who took responsibility for errors in retracted PNAS paper cites it…in error

Two more retractions in respiratory journal as University of Louisville completes investigation

Last July, we reported on four retractions by a group of researchers at the University of Louisville, and we noted that the scientists’ work was under investigation. That investigation has apparently concluded, according to a retraction notice in the American Journal of Respiratory Cell and Molecular Biology for two of their papers: Continue reading Two more retractions in respiratory journal as University of Louisville completes investigation

ORI: Former SUNY Upstate neuroscience dept. chair Miller manipulated data in four grant applications

Last month, we reported on two retractions by the former neuroscience and physiology department chair at the State University of New York (SUNY) Upstate Medical University in Syracuse. Both of the retractions were requested by the university after an investigation found that Michael W. Miller had committed misconduct.

Now, the Office of Research Integrity (ORI), which reviews misconduct investigations by NIH grantee institutions, has weighed in. As detailed in the Federal Register, ORI found that Miller falsified or fabricated data in four NIH grant applications, the two published (and now retracted) papers, and one manuscript submitted to the Proceedings of the National Academy of Sciences (PNAS). For example, he Continue reading ORI: Former SUNY Upstate neuroscience dept. chair Miller manipulated data in four grant applications

Update: Potti’s South Carolina medical license now listed as active

Updated at 1:40 p.m. Eastern: When original posted, this item reported, correctly, that the South Carolina Board of Medical Examiners’ website listed Anil Potti’s license as “suspended.” However, that status has now been changed to “active,” along with “No disciplinary action taken by the Board. This certifies that the above licensee is in good standing.” We are working to figure out why the status was changed.

Update, 1:55 p.m.: The Board tells us they made a mistake:

I looked into this matter and apparently this was a clerical error on our part because there are no public orders at this time. You should see this reflected on our licensee lookup system within 24 hours. Sorry for any confusion.

Anil Potti, the former Duke oncology researcher who lost his job at a South Carolina oncology practice earlier this week, has had his South Carolina medical license suspended, SCNow reports.

The South Carolina Board of Medical Examiners now lists Potti’s license — which he was granted on April 6, 2011 — as “suspended.” “active.”

We had a look at his other licenses. Continue reading Update: Potti’s South Carolina medical license now listed as active

Updated: Anil Potti out at Coastal Cancer Center; practice blames Duke for glowing recommendations

Anil Potti, the former Duke oncologist who has now retracted ten papers, is no longer listed as a staff member at the oncology practice that hired him sometime last year.

The development, first reported by Duke Check, follows a 60 Minutes segment last week focused on Potti and Duke. Duke Check also noted that a Myrtle Beach PR firm had promised a statement later today. Continue reading Updated: Anil Potti out at Coastal Cancer Center; practice blames Duke for glowing recommendations

Tenth Potti retraction appears, in Clinical Cancer Research

Anil Potti and his colleagues have retracted another paper, “Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma,” originally published in the December 15, 2009, issue of Clinical Cancer Research.

According to the notice: Continue reading Tenth Potti retraction appears, in Clinical Cancer Research

The Anil Potti retraction record so far

A 60 Minutes segment Sunday on Anil Potti has drawn national attention to the case, so we thought this would be a good time to compile all of the retractions and corrections in one place.

Duke has said that about a third of Potti’s 40-some-odd papers would be retracted, and another third would have “a portion retracted with other components remaining intact,” so this list will continue to grow. We’ll update it as we hear about new changes.

Retractions: Continue reading The Anil Potti retraction record so far